RxDoctor Payments DataLook up a doctor →

Sean Webster, PA

Medical · Bountiful, UTNPI 1063759215

Payments from drug & device makers

$8,917in general payments, 2019–2025

Across 579 payments — averaging $15.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$857
  • Lilly USA, LLC$774
  • Novo Nordisk$734
  • Boehringer Ingelheim$624
  • GSK$532
  • plus $4K from 53 others

What the payments were for

  • Food & beverage$8,892100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,917 in reported general payments places this provider in the 95th percentile of 263 medical providers in Utah.

See all medical providers in Utah

Medicare billing

Part B allowed, 2024
$30,277
Medicare patients
80
Services billed
473

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide42$50,988
FarxigaDapagliflozin Propanediol37$39,422
OzempicSemaglutide30$38,483
EliquisApixaban23$31,861
JardianceEmpagliflozin35$29,481
XareltoRivaroxaban14$20,476
MyrbetriqMirabegron15$11,199
Xigduo XrDapaglifloz Propaned/Metformin13$7,345
Atorvastatin Calcium278$3,083
Omeprazole110$2,321
Levothyroxine Sodium171$1,919
Amlodipine Besylate219$1,894
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,888
Tamsulosin Hcl136$1,655
Gabapentin83$1,557

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$774$50,98842 claims
AstraZenecaFarxiga$857$39,42237 claims
Novo NordiskOzempic$734$38,48330 claims
PfizerEliquis$206$31,86123 claims
Boehringer IngelheimJardiance$624$29,48135 claims
Johnson & JohnsonXarelto$155$20,47614 claims
Astellas Pharma US IncMyrbetriq$245$11,19915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 263 medical providers in Utah.

Other medical in Bountiful

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →